Table 3.
Correlation between the prevalence of autoantibody positivity and clinicopathological parameters in HCC.
| Parameters | Prevalence of autoantibody positivity |
|||||
|---|---|---|---|---|---|---|
| CENPF aAb | p value | HSP60 aAb | p value | IMP-2 aAb | p value | |
| Sex | ||||||
| Male | 180/236 (76.3%) | 0.407 | 185/236 (78.4%) | 0.538 | 51/75 (68.0%) | 0.794 |
| Female | 39/55 (71.0%) | 41/55 (74.6%) | 11/17 (64.7%) | |||
| Age | ||||||
| < 50 | 66/78 (84.6%)a | 0.025 | 158/168 (94.1%)a | 0.000 | 20/27 (74.1%) | 0.378 |
| ≥ 50 | 153/213 (71.8%) | 68/123 (55.3%) | 42/65 (64.6%) | |||
| HBV infection | ||||||
| HBV (+) | 198/260 (76.2%) | 0.305 | 200/260 (76.9%) | 0.380 | 57/83 (68.7%) | 0.672 |
| HBV (−) | 21/31 (67.7%) | 26/31 (8.39%) | 5/9 (55.6%) | |||
| Child-Pugh | ||||||
| A | 172/237 (72.6%)a | 0.046 | 180/237 (76.0%) | 0.189 | 48/68 (70.6%) | 0.272 |
| B | 34/40 (87.0%) | 33/40 (85.2%) | 8/16 (50.0%) | |||
| C | 13/14 (92.9%) | 13/14 (92.9%) | 6/8 (75.0%) | |||
| BCLC stage | ||||||
| A | 80/105 (76.2%) | 0.782 | 82/105 (78.1%) | 0.894 | 28/38 (73.7%) | 0.280 |
| B & C & D | 139/186 (74.7%) | 144/186 (77.4%) | 34/54 (63.0%) | |||
| Histology | ||||||
| Well differentiated | 31/32 (96.7%)a | 0.003 | 27/32 (84.4%) | 0.109 | 8/11 (72.7%) | 1.000 |
| Moderately/poorly differentiated | 82/114 (71.9%) | 80/114 (70.2%) | 21/31 (67.7%) | |||
| AFP | ||||||
| ≤ 20 ng/ml | 89/122 (73.0%) | 0.173 | 101/122 (82.8%) | 0.187 | 36/53 (67.9%) | 0.768 |
| 20–400 ng/ml | 84/115 (73.0%) | 84/115 (73.0%) | 24/37 (64.9%) | |||
| > 400 ng/ml | 46/54 (85.2%) | 41/54 (7.59%) | 12/16 (75.0%) | |||
| Tumor size | ||||||
| ≤ 5 cm | 83/109 (76.2%) | 0.786 | 85/109 (78.0%) | 0.920 | 28/38 (73.7%) | 0.280 |
| > 5 cm | 136/182 (74.7%) | 141/182 (77.5%) | 34/54 (63.0%) | |||
| Vascular invasion or metastasis | ||||||
| Yes | 32/46 (69.6%) | 0.330 | 36/46 (78.3%) | 0.916 | 5/7 (71.4%) | 1.000 |
| No | 187/245 (76.3%) | 190/245 (77.6%) | 57/86 (66.3%) | |||
a
With statistic significance. aAb: autoantibody.